Cite
HARVARD Citation
Lawitz, E. et al. (2013). A Phase I, Randomized, Placebo-Controlled, 3-Day, Ascending-Dose Study of Gs-9451, An Ns3/4A Protease Inhibitor, in Genotype 1 Hepatitis C Patients. Antiviral therapy. 18 (3), pp. 311-319. [Online].